

Martha Q Lacy

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7752132/martha-q-lacy-publications-by-citations.pdf>

Version: 2023-06-06

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

421
papers

8,670
citations

42
h-index

87
g-index

437
ext. papers

10,420
ext. citations

3.9
avg, IF

5.32
L-index

#	Paper	IF	Citations
4 ²¹	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008 , 111, 2516-20	2.1	1753
4 ²⁰	Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3751-7	2.1	593
4 ¹⁹	Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. <i>Journal of Clinical Oncology</i> , 2012 , 30, 989-95	2.1	582
4 ¹⁸	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013 , 88, 360-76	6.2	341
4 ¹⁷	Remission of disseminated cancer after systemic oncolytic virotherapy. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 926-33	6.2	202
4 ¹⁶	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017 , 129, 2111-2119	2.1	181
4 ¹⁵	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. <i>Blood</i> , 2012 , 119, 2100-5	2.1	181
4 ¹⁴	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. <i>Blood</i> , 1999 , 93, 1062-1066	6.6	147
4 ¹³	Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. <i>Blood</i> , 2014 , 124, 536-45	2.1	145
4 ¹²	Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 12-8	6.2	141
4 ¹¹	Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3196-203	2.1	139
4 ¹⁰	Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 1179-84	6.2	133
4 ⁰⁹	Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 323-41	6.2	123
4 ⁰⁸	Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4529-35	2.1	122
4 ⁰⁷	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 323-341	6.2	119
4 ⁰⁶	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018 , 8, 59	6.7	115
4 ⁰⁵	Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. <i>American Journal of Hematology</i> , 2010 , 85, 757-9	6.9	96

404	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 578-598	6.2	88
403	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. <i>JAMA Oncology</i> , 2017 , 3, 1257-1265	12.9	82
402	Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1054-81	6.2	81
401	Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. <i>Cancer Genetics and Cytogenetics</i> , 1999 , 113, 73-7		79
400	The clinical significance of cereblon expression in multiple myeloma. <i>Leukemia Research</i> , 2014 , 38, 23-8	2.1	72
399	Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 587-96	6.2	70
398	Comparison of Interleukin-1 Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>Blood</i> , 1999 , 93, 300-305	2.1	69
397	Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. <i>Journal of Clinical Oncology</i> , 1999 , 17, 262-7	2.1	68
396	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 531-536	10.3	60
395	Pomalidomide. <i>Blood</i> , 2013 , 122, 2305-9	2.1	56
394	Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1551-7	2.1	55
393	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016 , 91, 1123-1128	6.9	52
392	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019 , 54, 353-367	4.2	51
391	Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2001 , 68, 269-75	6.9	50
390	Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, 571-4	6.9	50
389	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018 , 32, 2240-2249	10.3	49
388	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017 , 92, 668-673	6.9	46
387	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017 , 130, 1198-1204	2.1	46

386	Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. <i>Archives of Dermatology</i> , 2005 , 141, 1277-82		46
385	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 187-194	6.9	45
384	A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. <i>Blood</i> , 2001 , 97, 2522-3	2.1	44
383	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 908-917	6.2	43
382	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018 , 97, 1417-1425	2.9	43
381	Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). <i>American Journal of Hematology</i> , 1997 , 56, 288-93	6.9	43
380	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, 1129-1134	6.9	42
379	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018 , 25, 86-92	2.6	40
378	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016 , 91, 585-9	6.9	40
377	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 116	6.7	38
376	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016 , 91, 984-8	6.9	37
375	Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. <i>Leukemia Research</i> , 2009 , 33, 1485-9	2.1	34
374	Clinical course and prognosis of non-secretory multiple myeloma. <i>European Journal of Haematology</i> , 2015 , 95, 57-64	3.6	33
373	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 472-483	6.2	33
372	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 598-605	2.1	32
371	Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFN β /IS. <i>Human Gene Therapy Clinical Development</i> , 2016 , 27, 111-22	3.1	30
370	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017 , 92, 50-55	6.9	30
369	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1354-1361	6.2	30

368	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019 , 33, 527-531	10.3	30
367	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 179-186	6.9	29
366	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 644-654	0.7	29
365	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015 , 90, 981-5	6.9	28
364	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3357-64	1.8	28
363	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. <i>Cancer</i> , 2016 , 122, 2197-205	6.2	28
362	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020 , 95, 497-502	6.9	27
361	Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000 , 9, 635-43		27
360	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020 , 4, 3509-3519	7.5	27
359	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019 , 187, 588-594	4.4	26
358	Acute lung toxicity related to pomalidomide. <i>Chest</i> , 2011 , 140, 529-533	1.2	26
357	Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. <i>Leukemia and Lymphoma</i> , 1999 , 35, 599-605	1.8	26
356	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015 , 90, 524-8	6.9	25
355	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1020-1026	6.9	25
354	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020 , 188, 394-403	4.4	23
353	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019 , 9, 32	6.7	22
352	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 55	6.7	22
351	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, 1146-1155	6.9	22

350	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020 , 34, 1373-1382	10.3	22
349	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1284-9	4.1	21
348	Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. <i>American Journal of Hematology</i> , 2017 , 92, 220-221	6.9	21
347	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020 , 27, 13-16	2.6	21
346	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016 , 91, 473-5	6.9	20
345	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012 , 120, 3138-3138	2.1	20
344	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 1930-1938	7.5	20
343	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017 , 102, 1439-1445	6.4	19
342	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020 , 34, 1135-1143	10.3	19
341	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 549-554	6.9	18
340	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 20	6.7	18
339	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018 , 32, 1811-1815	10.3	18
338	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016 , 101, 872-8	6.4	18
337	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281	6.9	18
336	Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. <i>American Journal of Hematology</i> , 2010 , 85, 95-6	6.9	17
335	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020 , 10, 82	6.7	17
334	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018 , 8, 125	6.7	17
333	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018 , 2, 3149-3154	7.5	17

332	First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016 , 127, 2936-8	2.1	16
331	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020 , 95, 310-315	6.9	16
330	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019 , 33, 790-794	10.3	16
329	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 41	6.7	16
328	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018 , 2, 769-776	7.5	16
327	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 811-814	10.3	15
326	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 1384-1393	6.9	15
325	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012 , 120, 201-201	2.1	15
324	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 1518-1523	6.9	15
323	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017 , 178, 888-895	4.4	14
322	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015 , 90, 888-91	6.9	14
321	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 455-464	6.2	13
320	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016 , 44, 32-9	2.1	13
319	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, E141-E143	6.9	13
318	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 106	6.7	13
317	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2360-2364	2.1	13
316	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 308-315	1.8	12
315	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 4	6.7	12

314	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2127-2132	2.1	12
313	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 56-58	6.2	12
312	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017 , 179, 98-105	4.4	12
311	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 864-864	2.1	12
310	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 70	6.7	11
309	Combination Therapy with CC-5013 (Lenalidomide; Revlimid) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , 2004 , 104, 331-331	2.1	11
308	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e108-e111	2.1	11
307	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019 , 33, 730-738	10.3	11
306	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017 , 92, 435-440	6.9	10
305	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019 , 185, 701-707	4.4	10
304	Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. <i>Leukemia and Lymphoma</i> , 2011 , 52, 560-6	1.8	10
303	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013 , 122, 407-407	2.1	10
302	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020 , 34, 1472-1475	10.3	10
301	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020 , 95, 1280-1287	6.9	10
300	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018 , 182, 71-77	4.4	9
299	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018 , 93, 17-22	6.9	9
298	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1066-1071	6.9	9
297	Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 194-194	2.1	9

296	Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. <i>Blood</i> , 2012 , 120, LBA-6-LBA-6	2.1	9
295	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 6581-6588	12.3	9
294	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016 , 101, 1102-9	6.4	9
293	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 380-385	4.4	9
292	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 306-311	6.9	9
291	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019 , 185, 254-260	4.4	8
290	Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 349-357.e2	0.7	8
289	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018 , 103, 1229-1234	6.4	8
288	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 889-894	6.9	8
287	New immunomodulatory drugs in myeloma. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 120-5	4.2	8
286	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 304-304	2.1	8
285	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015 , 126, 3050-3050	2.1	8
284	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021 , 11, 50	6.7	8
283	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1546-1577	6.2	8
282	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. <i>Scientific Reports</i> , 2020 , 10, 10250	4.7	7
281	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 587-594	4.2	7
280	First report of MYD88 somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 42-43	2.6	7
279	Natural history of amyloidosis isolated to fat and bone marrow aspirate. <i>British Journal of Haematology</i> , 2017 , 179, 170-172	4.4	7

278	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 2236-2244	7.5	7
277	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019 , 33, 1273-1277	10.3	7
276	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2039-2050	4.2	6
275	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1520-1525	2.1	6
274	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019 , 94, 751-756	6.9	6
273	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 637-642	6.9	6
272	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012 , 120, 3972-3972	2.1	6
271	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020 , 95, 4-9	6.9	6
270	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021 , 96, 1131-1136	6.9	6
269	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1775-1779	4.2	5
268	Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature. <i>Pulmonary Circulation</i> , 2015 , 5, 211-6	2.6	5
267	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2132-2137	4.2	5
266	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018 , 32, 1421-1426	10.3	5
265	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019 , 54, 442-447	4.2	5
264	Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 3475-3475	2.1	5
263	Immunoglobulin Variable Light Chain Restriction, Cytokine Expression and Plasma Cell-Stromal Cell Interactions in POEMS Syndrome Patients. <i>Blood</i> , 2008 , 112, 2744-2744	2.1	5
262	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2010 , 116, 1964-1964	2.1	5
261	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015 , 126, 1774-1774	2.1	5

260	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 4197-4197	2.1	5
259	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016 , 128, 3337-3337	2.1	5
258	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2021 ,	10.3	5
257	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, E8-E10	6.9	5
256	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 53-56	0.7	5
255	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. <i>American Journal of Hematology</i> , 2019 , 94, 424-430	6.9	5
254	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1144-1150	4.2	5
253	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021 , 195, 210-216	4.4	5
252	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1834-1839	6.2	4
251	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 1268-1272	10.3	4
250	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020 , 10, 52	6.7	4
249	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018 , 53, 326-333	4.2	4
248	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019 , 26, 101-102	2.6	4
247	A simple additive staging system for newly diagnosed multiple myeloma.. <i>Blood Cancer Journal</i> , 2022 , 12, 21	6.7	4
246	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. <i>Blood</i> , 2010 , 116, 370-370	2.1	4
245	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years.,. <i>Blood</i> , 2011 , 118, 3963-3963	2.1	4
244	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 677-687	6.2	4
243	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 322-326	7.5	4

242	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021 , 35, 1428-1437	10.3	4
241	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 40-41	2.6	3
240	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017 , 92, E507-E512	6.9	3
239	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1297-1304	4.2	3
238	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 596-601	0.7	3
237	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2157-2159	2.1	3
236	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019 , 125, 3574-3581	6.2	3
235	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020 , 136, 36-37	2.1	3
234	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma. <i>Blood</i> , 2005 , 106, 781-781	2.1	3
233	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. <i>Blood</i> , 2013 , 122, 3119-3119	2.1	3
232	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015 , 126, 3177-3177	2.1	3
231	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016 , 128, 2968-2968	2.1	3
230	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 3317-3317	2.1	3
229	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1077-1081	4.2	3
228	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021 , 106, 354-361	3.6	3
227	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 330-337	6.9	3
226	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). <i>Blood Cancer Journal</i> , 2021 , 11, 26	6.7	3
225	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021 , 5, 1029-1036	7.5	3

224	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 377-387	6.2	3
223	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021 , 96, 446-454	6.9	3
222	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2960-2967	1.8	2
221	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1402-1405 ^{2.1}	2.1	2
220	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. <i>Leukemia</i> , 2022 ,	10.3	2
219	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019 , 134, 1846-1846	2.1	2
218	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4386-4386 ^{2.1}	2.1	2
217	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 52-53	2.1	2
216	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 30-31	2.1	2
215	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 12-13	2.1	2
214	Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1171-1171	2.1	2
213	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. <i>Blood</i> , 2011 , 118, 2942-2942	2.1	2
212	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013 , 122, 3117-3117	2.1	2
211	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3210-3210	2.1	2
210	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016 , 128, 2972-2972	2.1	2
209	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021 , 138, 1639-1639	2.1	2
208	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3160-3160	2.1	2
207	Comparison of Interleukin-1 β Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>Blood</i> , 1999 , 93, 300-305	2.1	2

206	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021 , 96, 945-953	6.9	2
205	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 451-460.e2	0.7	2
204	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 589.e1-589.e6		2
203	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 928-935	4.2	2
202	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. <i>American Journal of Hematology</i> , 2021 , 96, E157-E162	6.9	2
201	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 44-45	2.6	1
200	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020 , 10, 124	6.7	1
199	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 1170	6.9	1
198	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018 , 93, 1207-1218	6.8	1
197	Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017 , 44, 1087-1091	1.6	1
196	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 183-188	2.6	1
195	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019 , 134, 72-72	2.1	1
194	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019 , 134, 4334-4334	2.1	1
193	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1905-1905	2.1	1
192	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020 , 136, 7-8	2.1	1
191	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 22-23	2.1	1
190	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004 , 104, 2927-2927	2.1	1
189	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. <i>Blood</i> , 2004 , 104, 892-892	2.1	1

188	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. <i>Blood</i> , 2007 , 110, 2477-2477	2.1	1
187	A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.. <i>Blood</i> , 2007 , 110, 3601-3601	2.1	1
186	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. <i>Blood</i> , 2008 , 112, 95-95	2.1	1
185	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. <i>Blood</i> , 2009 , 114, 956-956	2.1	1
184	Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score. <i>Blood</i> , 2010 , 116, 1892-1892	2.1	1
183	Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. <i>Blood</i> , 2010 , 116, 1893-1893	2.1	1
182	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). <i>Blood</i> , 2010 , 116, 3053-3053	2.1	1
181	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. <i>Blood</i> , 2010 , 116, 3557-3557	2.1	1
180	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. <i>Blood</i> , 2010 , 116, 863-863	2.1	1
179	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2011 , 118, 2887-2887	2.1	1
178	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. <i>Blood</i> , 2011 , 118, 2950-2950	2.1	1
177	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 3095-3095	2.1	1
176	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2011 , 118, 3981-3981	2.1	1
175	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. <i>Blood</i> , 2012 , 120, 1858-1858	2.1	1
174	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012 , 120, 946-946	2.1	1
173	Survival Outcomes Of Very Young (. <i>Blood</i> , 2013 , 122, 2136-2136	2.1	1
172	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013 , 122, 3095-3095	2.1	1
171	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015 , 126, 1830-1830	2.1	1

170	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 2082-2082	2.1	1
169	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016 , 128, 3272-3272	2.1	1
168	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016 , 128, 3444-3444	2.1	1
167	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016 , 128, 4627-4627	2.1	1
166	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021 , 11, 186	6.7	1
165	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2021 ,	6.9	1
164	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2021 ,	10.3	1
163	Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma.. <i>Blood</i> , 2004 , 104, 2412-2412	2.1	1
162	6q Deletion in Waldenstrom Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival.. <i>Blood</i> , 2005 , 106, 986-986	2.1	1
161	In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.. <i>Blood</i> , 2005 , 106, 2567-2567	2.1	1
160	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018 , 132, 1606-1606	2.1	1
159	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018 , 132, 2884-2884	2.1	1
158	Prognosis of Patients with Waldenstrom Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018 , 132, 4152-4152	1	
157	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019 , 134, 1800-1800	2.1	1
156	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019 , 134, 5490-5490	2.1	1
155	Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. <i>Blood</i> , 2010 , 116, 2970-2970	2.1	1
154	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2010 , 116, 987-987	2.1	1
153	TEMPI: A Reversible Syndrome Following Treatment with Bortezomib. <i>Blood</i> , 2012 , 120, 986-986	2.1	1

152	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020 , 95, E60-E62	6.9	1
151	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020 , 9, 8895-8901	4.7	1
150	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2975-2979	1.8	1
149	Belantamab mafodotin detection by MASS-FIX and immunofixation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, e430-e433	5.7	1
148	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021 , 62, 316-322	1.8	1
147	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021 , 11, 158	6.7	1
146	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020 , 136, 31-32	2.1	0
145	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018 , 132, 4460-4460	2.1	0
144	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020 , 136, 48-49	2.1	0
143	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3760-3760	2.1	0
142	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2711-2711	2.1	0
141	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 3774-3774	2.1	0
140	Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. <i>Cancer Treatment and Research Communications</i> , 2021 , 29, 100473	1.9	0
139	Depth of Response in Waldenström Macroglobulinemia. <i>Blood</i> , 2018 , 132, 4141-4141	2.1	0
138	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019 , 134, 3171-3171	2.1	0
137	Mayo Clinic Hematology Fellowship for Advanced Practice Providers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020 , 11, 395-400	0.6	0
136	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021 , 6, 857-864	0.9	0
135	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021 , 5, 2753-2759	7.5	0

134	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 274-277	4.2	o
133	Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021 , 96, E35-E38	6.9	o
132	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021 , 106, 433-436	3.6	o
131	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 308-315	1.8	o
130	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3011-3018	1.8	o
129	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 770.e1-770.e7		o
128	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , 2022 , 12, 59	6.7	o
127	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. <i>Leukemia and Lymphoma</i> , 2022 , 1-6	1.8	o
126	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 27-28	2.1	
125	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 9-10	2.1	
124	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020 , 136, 44-45	2.1	
123	Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. <i>Blood</i> , 2020 , 136, 34-35	2.1	
122	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 15-16	2.1	
121	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020 , 136, 14-15	2.1	
120	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020 , 136, 6-7	2.1	
119	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 21-22	2.1	
118	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 21-22	2.1	
117	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥75 Treated with Novel Agents. <i>Blood</i> , 2020 , 136, 12-13	2.1	

116	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020 , 136, 37-38	2.1
115	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. <i>Blood</i> , 2020 , 136, 1-2	2.1
114	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 41-42	2.1
113	Waldenström Macroglobulinemia in the Very Elderly (≥85 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020 , 136, 44-45	2.1
112	PET Imaging of a Unique Case of Multiple Myeloma in an Adolescent. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 730-731	1.6
111	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021 , 138, 2707-2707	2.1
110	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNENIS). <i>Blood</i> , 2021 , 138, 1333-1333	2.1
109	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021 , 138, 2700-2700	2.1
108	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. <i>Blood</i> , 2021 , 138, 1617-1617	2.1
107	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021 , 138, 819-819	2.1
106	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021 , 138, 3805-3805	2.1
105	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021 , 138, 3773-3773	2.1
104	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021 , 138, 3761-3761	2.1
103	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1632-1632	2.1
102	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1619-1619	2.1
101	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021 , 138, 543-543	2.1
100	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021 , 138, 1630-1630	2.1
99	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021 , 138, 119-119	2.1

- 98 The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. *Blood*, **2021**, 138, 2650-2650 2.1
- 97 Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. *Blood*, **2004**, 104, 928-928 2.1
- 96 The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. *Blood*, **2004**, 104, 1493-1493. 2.1
- 95 Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.. *Blood*, **2004**, 104, 4852-4852 2.1
- 94 Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2005**, 106, 5420-5420 2.1
- 93 Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. *Blood*, **2005**, 106, 3381-3381 2.1
- 92 Response to Rituximab in Type II Cryoglobulinemia.. *Blood*, **2005**, 106, 3499-3499 2.1
- 91 Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years.. *Blood*, **2005**, 106, 1173-1173 2.1
- 90 Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. *Blood*, **2005**, 106, 5422-5422 2.1
- 89 Treatment of Diuretic Refractory Pleural Effusions with Bevacizumab in Four Patients with Primary Systemic Amyloidosis (AL).. *Blood*, **2006**, 108, 5125-5125 2.1
- 88 Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.. *Blood*, **2006**, 108, 3500-3500 2.1
- 87 Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. *Blood*, **2006**, 108, 3587-3587 2.1
- 86 Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.. *Blood*, **2007**, 110, 1181-1181 2.1
- 85 Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. *Blood*, **2007**, 110, 1492-1492 2.1
- 84 Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. *Blood*, **2007**, 110, 2995-2995 2.1
- 83 Long-Term Survivorship with Active Multiple Myeloma. *Blood*, **2018**, 132, 1912-1912 2.1
- 82 Comparative Analysis of Staging Systems in AL Amyloidosis. *Blood*, **2018**, 132, 3228-3228 2.1
- 81 Treatment Facility Volume and Outcomes in Waldenström Macroglobulinemia. *Blood*, **2018**, 132, 622-622. 2.1

80	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3159-3159	
79	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3158-3158	2.1
78	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4449-4449	2.1
77	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2147-2147	2.1
76	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , 2018 , 132, 3226-3226	
75	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. <i>Blood</i> , 2018 , 132, 4613-4613	2.1
74	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4497-4497	2.1
73	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1902-1902	2.1
72	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , 2018 , 132, 5594-5594	2.1
71	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018 , 132, 5610-5610	2.1
70	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018 , 132, 3268-3268	2.1
69	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018 , 132, 3436-3436	2.1
68	Development of a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Utilizing a Needs-Based Assessment. <i>Blood</i> , 2018 , 132, 2236-2236	2.1
67	Patient-Reported Outcome Driven Case Management System for Hematology: A Prospective Study. <i>Blood</i> , 2018 , 132, 719-719	2.1
66	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4505-4505	2.1
65	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019 , 134, 5523-5523	2.1
64	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019 , 134, 1532-1532	
63	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4396-4396	2.1

62	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019 , 134, 3080-3080	2.1
61	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 5833-5833	2.1
60	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1904-1904	2.1
59	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019 , 134, 5532-5532	2.1
58	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 2197-2197	2.1
57	The Transcriptome of Immunomodulator-Resistant Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1772-1772	2.1
56	Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3061-3061	2.1
55	Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience. <i>Blood</i> , 2019 , 134, 2013-2013	2.1
54	Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2015 , 126, 1839-1839	2.1
53	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015 , 126, 3292-3292	2.1
52	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. <i>Blood</i> , 2015 , 126, 3039-3039	2.1
51	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015 , 126, 3317-3317	2.1
50	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4176-4176	2.1
49	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , 2015 , 126, 5303-5303	2.1
48	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. <i>Blood</i> , 2015 , 126, 3044-3044	2.1
47	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016 , 128, 5615-5615	2.1
46	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016 , 128, 996-996	2.1
45	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016 , 128, 3273-3273	2.1

44	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016 , 128, 3251-3251	2.1
43	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016 , 128, 1810-1810	2.1
42	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016 , 128, 3306-3306	2.1
41	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016 , 128, 1194-1194	2.1
40	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016 , 128, 3269-3269	2.1
39	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 3338-3338	2.1
38	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016 , 128, 3255-3255	2.1
37	Outcome of Very Young (<40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016 , 128, 5576-5576	2.1
36	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016 , 128, 2187-2187	2.1
35	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2267-2267	2.1
34	Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.. <i>Blood</i> , 2008 , 112, 2301-2301	2.1
33	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. <i>Blood</i> , 2010 , 116, 1965-1965	2.1
32	Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease. <i>Blood</i> , 2010 , 116, 3047-3047	2.1
31	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. <i>Blood</i> , 2010 , 116, 4518-4518	2.1
30	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. <i>Blood</i> , 2010 , 116, 2253-2253	2.1
29	Unraveling Early Mortality In Patients with AL Amyloidosis. <i>Blood</i> , 2010 , 116, 4990-4990	2.1
28	Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. <i>Blood</i> , 2010 , 116, 3468-3468	2.1
27	Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. <i>Blood</i> , 2010 , 116, 1958-1958	2.1

26	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. <i>Blood</i> , 2010 , 116, 3554-3554	2.1
25	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. <i>Blood</i> , 2010 , 116, 3469-3469	2.1
24	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2010 , 116, 3572-3572	2.1
23	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. <i>Blood</i> , 2011 , 118, 2945-2945	2.1
22	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. <i>Blood</i> , 2011 , 118, 4120-4120	2.1
21	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2011 , 118, 3101-3101	2.1
20	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. <i>Blood</i> , 2011 , 118, 2992-2992	2.1
19	The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. <i>Blood</i> , 2011 , 118, 2868-2868	2.1
18	Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. <i>Blood</i> , 2011 , 118, 636-636	2.1
17	IgD Amyloidosis: An Unrecognized Entity. <i>Blood</i> , 2011 , 118, 5079-5079	2.1
16	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. <i>Blood</i> , 2011 , 118, 2682-2682	2.1
15	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2012 , 120, 2973-2973	2.1
14	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012 , 120, 448-448	2.1
13	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). <i>Blood</i> , 2012 , 120, 600-600	2.1
12	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. <i>Blood</i> , 2012 , 120, 599-599	2.1
11	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1988-1988	2.1
10	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. <i>Blood</i> , 2013 , 122, 2151-2151	2.1
9	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1979-1979	2.1

- 8 Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. *Blood*, **2013**, 122, 3209-3209 2.1
- 7 Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. *Blood*, **2013**, 122, 754-754 2.1
- 6 Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). *Blood*, **2013**, 122, 3185-3185 2.1
- 5 Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. *Blood*, **2013**, 122, 1842-1842 2.1
- 4 Synchronous pityriasis lichenoides et varioliformis acuta and lymphoplasmacytic lymphoma: a distinct association. *International Journal of Dermatology*, **2021**, 60, 1550-1552 1.7
- 3 Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma. *Bone Marrow Transplantation*, **2021**, 56, 978-979 4.2
- 2 Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 309.e1-309.e5
- 1 Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. *Bone Marrow Transplantation*, **2022**, 4.2